keyword
MENU ▼
Read by QxMD icon Read
search

Peanut immunotherapy

keyword
https://www.readbyqxmd.com/read/28283151/immunotherapy-for-food-allergy-are-we-there-yet
#1
Yael Gernez, Anna Nowak-Węgrzyn
Current clinical research focuses on food allergen-specific immunotherapy through oral (OIT), sublingual (SLIT), or epicutaneous (EPIT) routes. Immunotherapy relies on the delivery of gradually increasing doses of specific allergens to induce desensitization (defined as temporary antigen hyporesponsiveness that depends on regular food ingestion) and, ultimately, tolerance (defined as the ability to ingest food without symptoms despite prolonged periods of avoidance or irregular intake). Although the majority of the patients treated with OIT achieve desensitization, only a minority achieves tolerance...
March 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28277274/therapeutic-reversal-of-food-allergen-sensitivity-by-mature-retinoic-acid-differentiated-dendritic-cell-induction-of-lag3-cd49b-foxp3-regulatory-t%C3%A2-cells
#2
Wojciech Dawicki, Chunyan Li, Jennifer Town, Xiaobei Zhang, John R Gordon
BACKGROUND: Anaphylaxis is a life-threatening condition for which we have limited therapeutic options. Although specific immunotherapy for food allergies is becoming more effective, it is still laborious and carries substantial risk of adverse events. On the other hand, regulatory dendritic cell (DC) therapy is effective in mouse models of allergic disease and has been shown to work with TH2 cells from atopic asthmatic patients. OBJECTIVE: We assessed whether DC immunotherapy could reverse food allergen sensitivity in mouse models to provide proof of concept relating to their use in the clinic...
October 20, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28226319/oral-and-sublingual-immunotherapy-potential-causes-for-eosinophilic-gastrointestinal-disorders
#3
Delara Babaie, Mehrnaz Mesdaghi, Makoto Nishino, Mahboubeh Mansouri, Motohiro Ebisawa
Food allergy is a common health problem worldwide, with increasing prevalence during recent decades. The only approved treatments for food allergy are food avoidance and administration of emergency medications in case of accidental exposure, which negatively affects patients' quality of life, so new treatments are highly desirable. Different food immunotherapy modalities have recently been used, with variable success rates in the induction of desensitization and tolerance, and different numbers and types of adverse reactions...
February 23, 2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28212503/lactobacillus-buchneri-s-layer-as-carrier-for-an-ara-h-2-derived-peptide-for-peanut-allergen-specific-immunotherapy
#4
Julia Anzengruber, Merima Bublin, Eva Bönisch, Bettina Janesch, Angelika Tscheppe, Matthias L Braun, Eva-Maria Varga, Christine Hafner, Heimo Breiteneder, Christina Schäffer
Peanut allergy is an IgE-mediated severe hypersensitivity disorder. The lack of a treatment of this potentially fatal allergy has led to intensive research on vaccine development. Here, we describe the design and initial characterization of a carrier-bound peptide derived from the most potent peanut allergen, Ara h 2, as a candidate vaccine. Based on the adjuvant capability of bacterial surface (S-) layers, a fusion protein of the S-layer protein SlpB from Lactobacillus buchneri CD034 and the Ara h 2-derived peptide AH3a42 was produced...
February 14, 2017: Molecular Immunology
https://www.readbyqxmd.com/read/28197701/-innovative-forms-of-specific-immunotherapy
#5
REVIEW
P Zieglmayer
The clinical efficacy of allergen-specific immunotherapy depends on tolerance induction. Treatment success is currently limited by treatment-related adverse reactions. Novel approaches mainly target improvement of tolerability in addition to optimized immunogenicity. For epicutaneous immunotherapy (EPIT), commercially available treatment extracts are applied to skin via a patch. The route exhibits excellent tolerability and good clinical efficacy. The first encouraging data on a peanut EPIT were published in 2016...
February 14, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28160513/the-clinical-and-immunological-effects-of-pru-p-3-slit-on-peach-and-peanut-allergy-in-patients-with-systemic-reactions
#6
F Gomez, G Bogas, M Gonzalez, P Campo, M Salas, A Diaz-Perales, M J Rodriguez, A Prieto, D Barber, M Blanca, M J Torres, C Mayorga
BACKGROUND: The peach non-specific lipid transfer protein (nsLTP), Pru p 3, is the primary sensitizer in fruits and responsible for severe reactions in the Mediterranean area. Peach allergy is frequently associated with other allergies such as peanut. Therefore, it is important to assess how specific immunotherapy to Pru p 3 could affect both peach and peanut tolerance. OBJECTIVES: To evaluate peach and peanut desensitization and immunological changes after one year of Pru p 3 sublingual immunotherapy (SLIT) in patients with systemic allergic reactions to peach and/or peanut...
February 4, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28132800/preparation-and-analysis-of-peanut-flour-used-in-oral-immunotherapy-clinical-trials
#7
Jelena P Berglund, Nicole Szczepanski, Anusha Penumarti, Ayeshia Beavers, Janelle Kesselring, Kelly Orgel, Bruce Burnett, A Wesley Burks, Michael Kulis
BACKGROUND: Oral immunotherapy (OIT) is an investigational therapeutic approach for the treatment of food allergies. Characterization of the drug product used in oral immunotherapy trials for peanut allergy has not been reported. OBJECTIVE: To quantify relative amounts of the major peanut allergens and microbial load present in peanut flour used in OIT trials and assess whether these parameters change over a 12-month period. We also anticipate that this report will serve as a guide for investigators seeking to conduct OIT trials under Food and Drug Administration-approved Investigational New Drug applications...
January 26, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28100257/food-specific-sublingual-immunotherapy-is-well-tolerated-and-safe-in-healthy-dogs-a-blind-randomized-placebo-controlled-study
#8
RANDOMIZED CONTROLLED TRIAL
E Maina, M Pelst, M Hesta, E Cox
BACKGROUND: Food allergies are increasing in prevalence but no treatment strategies are currently available to cure dogs with food allergy. Over the past decade, experimental food allergen-specific sublingual immunotherapy (FA-SLIT) has emerged as a potential treatment for food allergies in human medicine. However, FA-SLIT has not been investigated in dogs. Therefore, the objective of this study was to prospectively evaluate the safety, tolerability and dispenser sterility of FA-SLIT in healthy dogs before testing it in food allergic dogs...
January 18, 2017: BMC Veterinary Research
https://www.readbyqxmd.com/read/28091362/epicutaneous-immunotherapy-for-the-treatment-of-peanut-allergy-in-children-and-young-adults
#9
Stacie M Jones, Scott H Sicherer, A Wesley Burks, Donald Y M Leung, Robert W Lindblad, Peter Dawson, Alice K Henning, M Cecilia Berin, David Chiang, Brian P Vickery, Robbie D Pesek, Christine B Cho, Wendy F Davidson, Marshall Plaut, Hugh A Sampson, Robert A Wood
BACKGROUND: Peanut allergy is common, life-threatening, and without therapeutic options. We evaluated peanut epicutaneous immunotherapy (EPIT) by using Viaskin Peanut for peanut allergy treatment. OBJECTIVE: We sought to evaluate the clinical, safety, and immunologic effects of EPIT for the treatment of peanut allergy. METHODS: In this multicenter, double-blind, randomized, placebo-controlled study, 74 participants with peanut allergy (ages 4-25 years) were treated with placebo (n = 25), Viaskin Peanut 100 μg (VP100; n = 24) or Viaskin Peanut 250 μg (VP250; n = 25; DBV Technologies, Montrouge, France)...
October 20, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28042528/desensitization-for-peanut-allergies-in-children
#10
Rekha D Jhamnani, Pamela Frischmeyer-Guerrerio
Immunotherapy for peanut allergy has been an exploding topic of study within the last few years. Sublingual, epicutaneous, and oral immunotherapy are being investigated and show promise in the treatment of peanut allergy. Oral immunotherapy has shown the most clinical benefit; however, sublingual and epicutaneous immunotherapy appear to have the most favorable safety profiles. Most studies to date suggest that only a minority of subjects achieve sustained unresponsiveness to peanut after discontinuation of immunotherapy...
September 2016: Current Treatment Options in Allergy
https://www.readbyqxmd.com/read/28017628/eosinophilic-esophagitis-during-peanut-oral-immunotherapy-with-omalizumab
#11
Caitlin M Burk, Evan S Dellon, Pamela H Steele, Yamini V Virkud, Mike Kulis, A Wesley Burks, Brian P Vickery
No abstract text is available yet for this article.
March 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/27957697/benefit-of-slit-and-scit-for-allergic-rhinitis-and-asthma
#12
REVIEW
Giovanni Passalacqua, Giorgio Walter Canonica, Diego Bagnasco
Allergen immunotherapy (AIT) has been in use since more than one century, when Leonard Noon experimentally proved its efficacy in hayfever (Noon, in Lancet 1:1572-3, 1911). Since then, AIT was administered only as subcutaneous injections (SCIT) until the sublingual route (SLIT) was proposed in 1986. The use of SLIT was proposed following several surveys from the USA and UK that repeatedly reported fatalities due to SCIT (Lockey et al. in J Allergy Clin Immunol 75(1): 166, 1985; Lockey et al. in J Allergy Clin Immunol 660-77, 1985; Committee on the safety of medicines...
November 2016: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/27931280/safety-profile-of-oral-immunotherapy-with-cows-milk-and-hen-egg-a-10-year-experience-in-controlled-trials
#13
Giovanni B Pajno, Lucia Caminiti, Fernanda Chiera, Giuseppe Crisafulli, Giuseppina Salzano, Stefania Arasi, Giovanni Passalacqua
BACKGROUND: Oral immunotherapy (OIT) for food allergy is gaining interest due to the favorable clinical results reported with cow's milk, hen egg and peanut. The safety of the procedure remains a critical aspect that can limit the introduction of OIT in clinical practice. OBJECTIVE: We described herein, in detail, the occurrence and characteristics of adverse events (AE) with OIT in children who participated in controlled trials at our unit. METHODS: The clinical records of 68 children who received active treatment (40 for cow's milk and 28 for hen egg) were carefully reviewed...
September 2016: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/27916627/peanut-oral-immunotherapy-decreases-ige-to-ara-h-2-and-ara-h-6-but-does-not-enhance-sensitization-to-cross-reactive-allergens
#14
Riikka Uotila, Anna Kaarina Kukkonen, Dario Greco, Anna Susanna Pelkonen, Mika Juhani Mäkelä
No abstract text is available yet for this article.
December 1, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27859599/double-blind-placebo-controlled-challenge-showed-that-peanut-oral-immunotherapy-was-effective-for-severe-allergy-without-negative-effects-on%C3%A2-airway-inflammation
#15
Anna Kaarina Kukkonen, Riikka Uotila, Leo Pekka Malmberg, Anna Susanna Pelkonen, Mika Juhani Mäkelä
AIM: This study examined the efficacy and the safety of peanut oral immunotherapy (OIT). METHODS: We recruited 60 patients aged six years to 18 years who had a moderate-to-severe reaction to a double-blind placebo-controlled peanut challenge: 39 received OIT during an eight-month build-up phase and maintenance phase and 21 controls avoided peanuts. We measured specific immunoglobulin E and G4 (IgE and IgG4) to peanuts and to Ara h 1, 2, 3, 8 and 9 and monitored adverse events, bronchial hyper-responsiveness (BHR) to methacholine and fractional concentrations of exhaled nitric oxide (FeNO)...
February 2017: Acta Paediatrica
https://www.readbyqxmd.com/read/27628022/the-use-of-omalizumab-in-food-oral-immunotherapy
#16
Roxane Labrosse, François Graham, Anne Des Roches, Philippe Bégin
Food allergy is an important health issue that affects up to 8 % of the population. The management of allergic patients involves allergen avoidance and prompts the treatment of accidental reactions, as no curative treatment is available so far in routine practice. Oral immunotherapy (OIT) is a promising therapeutic alternative, but it is associated with frequent allergic reactions and cost-effectiveness issues. In hopes of reducing such reactions, a number of trials have used omalizumab, an anti-IgE monoclonal humanized antibody, as adjunctive therapy in OIT...
September 14, 2016: Archivum Immunologiae et Therapiae Experimentalis
https://www.readbyqxmd.com/read/27609658/omalizumab-facilitates-rapid-oral-desensitization-for-peanut-allergy
#17
Andrew J MacGinnitie, Rima Rachid, Hana Gragg, Sara V Little, Paul Lakin, Antonella Cianferoni, Jennifer Heimall, Melanie Makhija, Rachel Robison, R Sharon Chinthrajah, John Lee, Jennifer Lebovidge, Tina Dominguez, Courtney Rooney, Megan Ott Lewis, Jennifer Koss, Elizabeth Burke-Roberts, Kimberly Chin, Tanya Logvinenko, Jacqueline A Pongracic, Dale T Umetsu, Jonathan Spergel, Kari C Nadeau, Lynda C Schneider
BACKGROUND: Peanut oral immunotherapy is a promising approach to peanut allergy, but reactions are frequent, and some patients cannot be desensitized. The anti-IgE medication omalizumab (Xolair; Genentech, South San Francisco, Calif) might allow more rapid peanut updosing and decrease reactions. OBJECTIVE: We sought to evaluate whether omalizumab facilitated rapid peanut desensitization in highly allergic patients. METHODS: Thirty-seven subjects were randomized to omalizumab (n = 29) or placebo (n = 8)...
March 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27609653/novel-baseline-predictors-of-adverse-events-during-oral-immunotherapy-in-children-with-peanut-allergy
#18
Yamini V Virkud, A Wesley Burks, Pamela H Steele, Lloyd J Edwards, Jelena P Berglund, Stacie M Jones, Amy M Scurlock, Tamara T Perry, Robert D Pesek, Brian P Vickery
BACKGROUND: Though peanut oral immunotherapy (OIT) is a promising investigational therapy, its potential is limited by substantial adverse events (AEs), which are relatively understudied. OBJECTIVE: A retrospective analysis was conducted, pooling data from 3 pediatric peanut OIT trials, comprising the largest analysis of peanut OIT safety to date. METHODS: We pooled data from 104 children with peanut allergy from 3 peanut OIT studies. We catalogued AEs from parental reports, daily symptom diaries, and dose escalations...
March 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27599211/low-dose-immunotherapy-in-very-young-children-to-treat-peanut-allergy
#19
Brian P Vickery
No abstract text is available yet for this article.
December 2016: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/27522159/early-oral-immunotherapy-in-peanut-allergic-preschool-children-is-safe-and-highly-effective
#20
Brian P Vickery, Jelena P Berglund, Caitlin M Burk, Jason P Fine, Edwin H Kim, Jung In Kim, Corinne A Keet, Michael Kulis, Kelly G Orgel, Rishu Guo, Pamela H Steele, Yamini V Virkud, Ping Ye, Benjamin L Wright, Robert A Wood, A Wesley Burks
BACKGROUND: Oral immunotherapy (OIT) is an effective experimental food allergy treatment that is limited by treatment withdrawal and the frequent reversibility of desensitization if interrupted. Newly diagnosed preschool children may have clinical and immunological characteristics more amenable to treatment. OBJECTIVE: We sought to test the safety, effectiveness, and feasibility of early OIT (E-OIT) in the treatment of peanut allergy. METHODS: We enrolled 40 children aged 9 to 36 months with suspected or known peanut allergy...
January 2017: Journal of Allergy and Clinical Immunology
keyword
keyword
113759
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"